Thanatin
Based on 1 Customer Validation
Thanatin is an inducible cationic antimicrobial peptide. Thanatin is a pathogen-inducible single-disulfide-bond-containing β-hairpin AMP. Thanatin displays broad-spectrum activity against both Gram-negative and Gram-positive bacteria as well as against various species of fungi with MICs of 0.3-40 µM, 0.6-40 µM and 0.6-20 µM, respectively. Thanatin has the property of competitive replacement of divalent cations from bacterial outer membrane (OM), leading to OM disruption.
For research use only. We do not sell to patients.
- Purity : 99.71%
- CAS No.: 214542-43-5
- Formula: C103H177N35O27S3
- Molecular Weight:2433.92
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
Thanatin is strongly cationic (pI of 10.48) and contains a distinct short eight-residue basic loop created through a disulfide bond formation between residues Cys11 and Cys18 at the C-terminus. [1].
Thanatin exhibits potent inhibitory effect on the growth of all New Delhi metallo-β-lactamase-1 (NDM-1)-producing E. coli and K. pneumoniae strains at 0.4-3.2 μM of the minimum inhibitory concentration (MIC) values[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice aged 8-10 weeks and weighing 18-22 g with CFU E. coli XJ141026
-
Dosage:1, 3, 6 mg/kg
-
Administration:Intraperitoneally injected; at 1 and 6 h
-
Result:1, 3, and 6 mg/kg markedly increased the survival rate from 0 to 30%, 70%, and 100%, respectively.
Showed that the bacterial titers decreased with increasing drug dose.
Rescued the pathological damages (large amounts of inflammatory cell infiltration, alveolar fusion, congestion in the spleen red pulp area, hepatic sinusoidal dilation and congestion) in a dose-dependent manner.
Chemical Information
-
CAS No. 214542-43-5
-
Appearance Solid
-
Molecular Weight 2433.92
-
Formula C103H177N35O27S3
-
Color White to off-white
-
Sequence
Gly-Ser-Lys-Lys-Pro-Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Arg-Thr-Gly-Lys-Cys-Gln-Arg-Met (Disulfide bridge:Cys11-Cys18)
-
Sequence Shortening
GSKKPVPIIYCNRRTGKCQRM (Disulfide bridge:Cys11-Cys18)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
H2O : ≥ 100 mg/mL (41.09 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rachita Dash, et al. Thanatin: An Emerging Host Defense Antimicrobial Peptide with Multiple Modes of Action. Int J Mol Sci. 2021 Feb 3;22(4):1522. [Content Brief]
[2]. Bo Ma, et al. The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-β-lactamase. Nat Commun. 2019 Aug 6;10(1):3517. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.4109 mL | 2.0543 mL | 4.1086 mL | 10.2715 mL |
| 5 mM | 0.0822 mL | 0.4109 mL | 0.8217 mL | 2.0543 mL | |
| 10 mM | 0.0411 mL | 0.2054 mL | 0.4109 mL | 1.0271 mL | |
| 15 mM | 0.0274 mL | 0.1370 mL | 0.2739 mL | 0.6848 mL | |
| 20 mM | 0.0205 mL | 0.1027 mL | 0.2054 mL | 0.5136 mL | |
| 25 mM | 0.0164 mL | 0.0822 mL | 0.1643 mL | 0.4109 mL | |
| 30 mM | 0.0137 mL | 0.0685 mL | 0.1370 mL | 0.3424 mL | |
| 40 mM | 0.0103 mL | 0.0514 mL | 0.1027 mL | 0.2568 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.